User:Mr. Ibrahem/Zonisamide

From Wikipedia, the free encyclopedia
Mr. Ibrahem/Zonisamide
Ball-and-stick model of the zonisamide molecule
Clinical data
Trade namesZonegran, others
AHFS/Drugs.comMonograph
MedlinePlusa603008
License data
Pregnancy
category
  • AU: D
Routes of
administration		By mouth
Drug classSulfonamide[1]
Legal status
Legal status
Pharmacokinetic data
Bioavailability~100%[2]
Protein binding40%[2]
MetabolismLiver through CYP3A4[2]
Elimination half-life63 hours in plasma[2]
ExcretionKidney (62%); Faeces (3%)[2]
Identifiers
  • benzo[d]isoxazol-3-ylmethanesulfonamide
Chemical and physical data
FormulaC8H8N2O3S
Molar mass212.22 g·mol−1
3D model (JSmol)
Melting point162 °C (324 °F)
  • O=S(=O)(N)Cc2noc1ccccc12
  • InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12) checkY
  • Key:UBQNRHZMVUUOMG-UHFFFAOYSA-N checkY
  (verify)

Zonisamide, sold under the brand name Zonegran, is a medication used in addition to other medications to treat epilepsy, specifically partial seizures.[1] There is also some evidence for its use in Parkinson's.[3] It is taken by mouth.[1]

Common side effects include abdominal pain, nausea, constipation, dry mouth, and dizziness.[1] Other side effects may include hair loss, nystagmus, and bone marrow disorders.[4] Use during pregnancy may harm the baby and use during breastfeeding is not recommended.[5] It is in the sulfonamide family of chemicals and is not recommended in people allergic to these.[1][4]

Zonisamide was approved for medical use in the United States in 2000.[1] It is available as a generic medication.[6] In the United States it costs less than 20 USD per month as of 2021.[6] It is also relatively inexpensive in the United Kingdom.[4]

References[edit]

  1. ^ a b c d e f g h "Zonisamide Monograph for Professionals". Drugs.com. Archived from the original on 27 February 2021. Retrieved 4 August 2021.
  2. ^ a b c d e "Zonegran Product Information" (PDF). TGA eBusiness Services. SciGen (Australia) Pty Ltd. 4 April 2013. Archived from the original on 15 October 2018. Retrieved 18 November 2013.
  3. ^ Grover ND, Limaye RP, Gokhale DV, Patil TR (November–December 2013). "Zonisamide: a review of the clinical and experimental evidence for its use in Parkinson's disease". Indian Journal of Pharmacology. 45 (6): 547–55. doi:10.4103/0253-7613.121266. PMC 3847242. PMID 24347760.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  4. ^ a b c BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 350. ISBN 978-0-85711-369-6.{{cite book}}: CS1 maint: date format (link)
  5. ^ "Zonisamide (Zonegran) Use During Pregnancy". Drugs.com. Archived from the original on 2 February 2021. Retrieved 5 August 2021.
  6. ^ a b "Zonisamide Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 5 August 2021.
Retrieved from "https://en.wikipedia.org/w/index.php?title=User:Mr._Ibrahem/Zonisamide&oldid=1152894565"